1. |
[1]Beverley S,George W,Ann C,Nicole Z,Vivian R,Lauren G,Zulma O,Joan P,Jonathan A,Peter T,Gordon G.Meta-Analysis of Calcium Supplementation for the Prevention of Postmenopausal Osteoporosis[J].Endocrine Reviews,2002; 23 (4):552-559.
|
2. |
[2]Emmanuel P,George W,Beverley S,William G,Bruce W,Nicole Z,Ann C,Jonathan A,Peter T,Robert J,Carol G,Gordon G.Meta-Analysis of the Efficacy of Vitamin D Treatment in Preventing Osteoporosis in Postmenopausal Women[J].Endocrine Reviews,2002; 23 (4):560-569.
|
3. |
[3]Chapuy MC,Arlot ME,Duboeuf F,Brun J,Crouzet B,Arnaud S,Delmas PD,Meunier PJ.Vitamin D3 and calcium to prevent hip fractures in elderly women[J].N Engl J Med,1992; 327(23):1 637-1 642.
|
4. |
[4]Lips P,Wilco C,Graafmans MS,Bezemer PD,Bouter LM.Vitamin D supplementation and fracture incidence in elderly persons[J].Ann Intern Med,1996; 124(4):400-406.
|
5. |
[5]Ann C,George W,Andrew W,Lauren G,Nicole Z,Vivian R,Dennis B,Jonathan A,Beverley S,Peter T.Gordon G.Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women[J].Endocrine Reviews,2002; 23 (4):508-516.
|
6. |
[6]Black DM,Cummings SR,Karpf DB,Cauley JA,Thompson DE,Nevitt MC,Bauer DC,Genant HK,Haskell WL,Marcus R,Ott SM,Torner JC,Quandt SA,Reiss TF,Ensrud KE.Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures[J].Fracture Intervention Trial Research Group.Lancet,1996; 348(9 041):1 535-1 541.
|
7. |
[7]Ann C,Peter T,Jonathan A,Bruce W,Nicole Z,Alexandra P,Vivian R,Beverley S,George W,Gordon G.Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis[J].Endocrine Reviews,2002; 23 (4):517-523.
|
8. |
[8]McClung MR,Geusens P,Miller P,Zippel H,Bensen WG,Roux C,Adami S,Fogelman I,Diamond T,Eastell R,Meunier PJ,Wasnich RD,Greenwald M,Kaufman JM,Chesnut CH,Reginster JY.Effect of risedronate on the risk of hip fracture in elderly women[J].N Engl J Med,2001; 344(5):333-340.
|
9. |
[9]Cranney A,Welch V,Adachi JD,Guyatt G,Krolicki N,Griffith L,Shea B,Tugwell P,Wells G.Etidronate for treating and preventing postmenopausal osteoporosis(Cochrane Review) [M/CD].The Cocrane Library,Issue 3,2003.
|
10. |
[10]Ann C,Peter T,Nicole Z,Vivian R,Bruce W,Beverley S,George W,Jonathan A,Lisa W,Gordon G.l.Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis[J].Endocrine Reviews,2002; 23 (4):540-551.
|
11. |
[11]Chesnut CH 3rd,Silverman S,Andriano K,Genant H,Gimona A,Harris S,Kiel D,LeBoff M,Maricic M,Miller P,Moniz C,Peacock M,Richardson P,Watts N,Baylink D.A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis:the prevent recurrence of osteoporotic fractures study.PROOF Study Group[J].Am J Med,2000; 109(4):267-276.
|
12. |
[12]George W,Peter T,Beverley S,Gordon G,Joan P,Nicole Z,Vivian R,David H,Diane O,Ann C.Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women[J].Endocrine Reviews,2002; 23 (4):529-539.
|
13. |
[13]Cauley JA,Robbins J,Chen Z,Cummings SR,JacksonRD,LaCroix AZ,LeBoff M,Lewis CE,McGowan J,Neuner J,Pettinger M,Stefanick ML,Wactawski-Wende J,Watts NB.Effects of estrogen plus progestin on risk of fracture and bone mineral density:the Women’s Health Initiative randomized trial[J].JAMA,2003; 290(13):1 729-1 738.
|
14. |
[14]Chlebowski RT,Hendrix SL,Langer RD,Stefanick ML,Gass M,Lane D,Rodabough RJ,Gilligan MA,Cyr MG,Thomson CA,Khandekar J,Petrovitch H,McTiernan A.Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women:the Women’s Health Initiative Randomized Trial[J].JAMA,2003; 289(24):3 243-3 253.
|
15. |
[15]Wassertheil-Smoller S,Hendrix SL,Limacher M,Heiss G,Kooperberg C,Baird A,Kotchen T,Curb JD,Black H,Rossouw JE,Aragaki A,Safford M,Stein E,Laowattana S,Mysiw WJ.Effect of estrogen plus progestin on stroke in postmenopausal women:the Women’s Health Initiative:a randomized trial[J].JAMA,2003; 289(20):2 673-2 684.
|
16. |
[16]Hulley S,Grady D,Bush T,Furberg C,Herrington D,Riggs B,Vittinghoff E.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.Heart and Estrogen/progestin Replacement study (HERS) Research Group[J].JAMA,1998; 280(7):605-613.
|
17. |
[17]Ann C,Peter T,Nicole Z,Vivian R,Bruce W,Jonathan A,George W,Beverley S,Gordon G.Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis[J].Endocrine Reviews,2002; 23 (4):524-528.
|
18. |
[18]Ettinger B,Black DM,Mitlak BH,Knickerbocker RK,Nickelsen T,Genant HK,Christiansen C,Delmas PD,Zanchetta JR,Stakkestad J,Gluer CC,Krueger K,Cohen FJ,Eckert S,Ensrud KE,Avioli LV,Lips P,Cummings SR.Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene[J].JAMA,1999; 282(7):637-645.
|
19. |
[19]Neer RM,Arnaud CD,Zanchetta JR,Prince R,Gaich GA,Reginster JY,Hodsman AB,Eriksen EF,Ish-Shalom S,Genant HK,Wang O,Mitlak BH.Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis[J].N Engl J Med,2001; 344(19):1 434-1 441.
|
20. |
[20]Jean-JB,Gregory AG,Wim HS,Kulkarni PM,Miller PD,Peretz A,Dore RK,Correa-Rotter R,Papaioannou A,Cumming DC,Hodsman AB.A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide[Recombinant Human Parathyroid Hormone (1-34)] with Alendronate in Postmenopausal Women with Osteoporosis[J].J Clin Endocrinol Metab,2002; 87(10):4 528-4 535.
|
21. |
[21]Haguenauer D,Welch V,Shea B,Tugwell P,Wells G.Fluoride for treating postmenopausal osteoporosis (Cochrane Review) [M/CD].The Cocrane Library,Issue 3,2003.
|